Does Fetal Exposure to SSRIs or Maternal Depression Impact Infant Growth?

• Published in: The American journal of psychiatry 2013-05, Vol.170 (5), p.485-493
• Main Authors: Wisner, Katherine L., Bogen, Debra L., Sit, Dorothy, McShea, Mary, Hughes, Carolyn, Rizzo, David, Confer, Andrea, Luther, James, Eng, Heather, Wisniewski, Stephen W.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Adult and adolescent clinical studies; Antidepressants; Antidepressive Agents, Second-Generation - adverse effects; Antidepressive Agents, Second-Generation - therapeutic use; Biological and medical sciences; Body Size - drug effects; Case-Control Studies; Depression; Depressive Disorder, Major - drug therapy; Female; Fetal Development - drug effects; Head - growth & development; Humans; Infant; Infant, Newborn; Male; Medical sciences; Mental depression; Mood disorders; Pregnancy; Prenatal development; Prenatal Exposure Delayed Effects - chemically induced; Prospective Studies; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Serotonin Uptake Inhibitors - adverse effects; Serotonin Uptake Inhibitors - therapeutic use
• ISSN: 0002-953X; 1535-7228
• DOI: 10.1176/appi.ajp.2012.11121873

In utero exposure to a mother's untreated major depression or SSRI antidepressants did not affect infant weight, length, or head circumference in the first year of life, suggesting that factors regulating infant growth are robust enough not to be perturbed by either option. ObjectiveThe aim of this study was to compare the growth of infants born to women with antenatal major depressive disorder, either untreated or treated with selective serotonin reuptake inhibitor (SSRI) antidepressants, and infants born to a nondepressed, nonmedicated comparison group across the first year of life.MethodIn this prospective observational study, pregnant women were evaluated at weeks 20, 30, and 36 of gestation, and mother and infant pairs were assessed at 2, 12, 26, and 52 weeks postpartum. Three nonoverlapping groups of women were defined according to their pregnancy exposures: 1) no SSRI and no depression (N=97), 2) SSRI (N=46), and 3) major depression without SSRI (N=31). Maternal demographic and clinical characteristics and newborn outcomes were compared across exposure groups. Infant weight, length, and head circumference were measured by a physician or physician’s assistant who was blind to depression and SSRI exposure status at each postpartum time point.ResultsBoth adjusted and unadjusted analyses revealed neither antenatal major depression nor SSRI exposure was significantly associated with infant weight, length, or head circumference relative to nonexposure to either. In addition, the interaction of group and prepregnancy body mass index was also evaluated, and no significant synergistic effect was identified. Similarly, no differential effect of group over time was observed for weight, length, or head circumference.ConclusionsIn utero exposure to major depression or SSRI antidepressants did not affect infant growth with respect to weight, length, or head circumference from birth through 12 months of age.